Guardant Health, Inc. Enters into an Amendment 5 to Supply Agreement with Illumina, Inc
January 07, 2021 at 09:02 pm
Share
On January 1, 2021, Guardant Health, Inc. entered into an Amendment 5 to Supply Agreement with Illumina, Inc. (Illumina), which amends that certain Supply Agreement, dated September 15, 2014, by and between the Company and Illumina, as amended (the “Supply Agreement”), pursuant to which Illumina provides the Company products and services used for certain research and clinical activities, including certain sequencers, equipment and other materials the Company uses in its laboratory operations. The Amendment provides for, among other things, extending the term of the Supply Agreement to January 2033. The term of the Supply Agreement will automatically renew for successive one-year periods after January 2033 unless the Supply Agreement is terminated earlier in accordance with its terms or either party provides notice of non-renewal to the other party of not less than 12 months prior to the date such renewal would otherwise take effect. Under the terms of the Amendment, the Company may also terminate the Supply Agreement for convenience upon 90 days’ prior written notice. The Amendment also updated the list of specific hardware and consumables, including associated pricing terms for each, to be provided by Illumina to the Company.
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).